公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2013 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | Ying-Chun Shen ; DA-LIANG OU ; CHIUN HSU ; Lin K.-L.; Chang C.-Y.; CHING-YU LIN ; Liu S.-H.; ANN-LII CHENG | British Journal of Cancer | 154 | 146 | |
2010 | Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach | Ying-Chun Shen ; CHIUN HSU ; Chen L.-T.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Journal of Hepatology | 122 | 113 | |
2011 | Antiangiogenic strategies for the treatment of hepatocellular carcinoma | CHIUN HSU ; Ying-Chun Shen ; ANN-LII CHENG | Targeted Therapies for Hepatocellular Carcinoma | 0 | 0 | |
2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; YING-CHUN SHEN ; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 4 | |
2010 | Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B | BOR-SHENG KO ; Chang T.-C.; Chen C.-H.; Liu C.-C.; Kuo C.-C.; CHIUN HSU ; Ying-Chun Shen ; Shen T.-L.; Golubovskaya V.M.; Chang C.-C.; Shyue S.-K.; Liou J.-Y. | Life Sciences | 39 | 36 | |
2018 | Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): Preclinical activity in the Myc-CaP model | Ying-Chun Shen ; Ghasemzadeh A.; Kochel C.M.; Nirschl T.R.; Francica B.J.; Lopez-Bujanda Z.A.; Carrera Haro M.A.; Tam A.; Anders R.A.; Selby M.J.; Korman A.J.; Drake C.G. | Prostate Cancer and Prostatic Diseases | 36 | 35 | |
2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
2012 | A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression | YING-CHUN SHEN ; CHIUN HSU ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Oncology | 34 | 29 | |
2006 | Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: Implication from age-period-cohort analysis | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; RUEY-LONG HONG ; Chang C.-J.; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 67 | 51 | |
2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
2023 | Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis | Peng, Shang-Hsuan; CHING-HUNG LIN ; I-CHUN CHEN ; YING-CHUN SHEN ; DWANG-YING CHANG ; WEI-WU CHEN ; Huang, Shu-Min; Hu, Fu-Chang; YEN-SHEN LU | Cancer medicine | 0 | 0 | |
2011 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | CHAO-YU HSU ; Ying-Chun Shen ; CHIH-WEI YU ; CHIUN HSU ; Hu F.-C.; CHIH-HUNG HSU ; BANG-BIN CHEN ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Journal of Hepatology | 106 | 100 | |
2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 56 | 58 | |
2023 | Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors | DE-RUI HUANG ; BIN-CHI LIAO ; Hsu, Wei-Hsun; CHING-YAO YANG ; YEN-TING LIN ; SHANG-GIN WU ; TZU-HSIU TSAI ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG ; ANN-LII CHENG ; YING-CHUN SHEN | Oncology | |||
2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
2013 | erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5) | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; KUN-HUEI YEH | Gastric Cancer | 0 | 0 | |
2021 | Evolution of systemic treatment for advanced hepatocellular carcinoma | Wu T.-C.; YING-CHUN SHEN ; ANN-LII CHENG | Kaohsiung Journal of Medical Sciences | 10 | 9 | |
2012 | Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; KUN-HUEI YEH | Gastric Cancer | 19 | 18 | |
2010 | Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Contemporary Clinical Trials | 41 | 37 |